Establishment Labs Launches Motiva Implants in U.S.

Establishment Labs Holdings ( (ESTA) ) has provided an announcement.

On June 12, 2025, Establishment Labs Holdings Inc. held an analyst and investor event in New York City, where they announced the successful launch of Motiva implants in the United States, with over 1,000 surgeons now offering the product. The company projects $9.5 million to $10 million in sales for the second quarter of fiscal 2025 and plans to seek FDA approval for Motiva Implants for reconstruction use by the fourth quarter of 2025. Additionally, the launch of Preservé in the U.S. is anticipated in the first half of 2026. These developments are expected to strengthen the company’s position in the breast aesthetics and reconstruction market, with a focus on achieving significant growth and efficiency in operations.

The most recent analyst rating on (ESTA) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Establishment Labs Holdings stock, see the ESTA Stock Forecast page.

Spark’s Take on ESTA Stock

According to Spark, TipRanks’ AI Analyst, ESTA is a Neutral.

The overall score is influenced primarily by financial performance and technical analysis. Strong revenue growth is offset by profitability challenges and high liabilities. Positive technical indicators support a bullish outlook, while strategic leadership changes are promising but yet to demonstrate impact.

To see Spark’s full report on ESTA stock, click here.

More about Establishment Labs Holdings

Establishment Labs Holdings Inc. operates in the medical technology industry, focusing on breast aesthetics and reconstruction products. The company is known for its Motiva implants, which are widely used in over 90 countries, and it is expanding its market presence in the United States.

Average Trading Volume: 498,021

Technical Sentiment Signal: Sell

Current Market Cap: $1.12B

See more data about ESTA stock on TipRanks’ Stock Analysis page.